Back |
home / stock / dmac / dmac message board
Subject | By | Source | When |
---|---|---|---|
John Mauldins Biotech company -- DiaMedica (TSXV:DMA; OTCQB:$DMCAF) | Regis999 | investorshub | 04/16/2018 6:06:52 PM |
Emylers: DMCAF Financials 07/16/2014 09:48:28 Diamedica, Inc. Period Ending Total Revenue Cost of Re | Emylers | investorshangout | 07/16/2014 2:48:25 PM |
Stock Tracker: Latest Diamedica Inc (DMCAF) Headlines Aon Benfield Exec: China Moving Towards Second | Stock_Tracker | investorshangout | 03/09/2014 7:03:21 PM |
chartguy89: DMCAF 0.832 Stock Charts $DMCAF 1 Month Chart | chartguy89 | investorshangout | 03/07/2014 1:57:30 AM |
chartguy89: DMCAF Stock Charts Last: -0.031 Tuesday, February 25, 2014 at 10:10:33 AM $DMCAF | chartguy89 | investorshangout | 02/25/2014 3:10:44 PM |
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of...
Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 ...
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developi...